AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05550142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
Description: 50μg/dose
Study NCT05550142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose
Description: 100μg/dose
Study NCT05550142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution
Study NCT05242328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided erector spinae plane block
Description: Ultrasound-guided erector spinae plane block
Study NCT05242328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical thoracoscopic intercostal nerve block
Description: surgical thoracoscopic intercostal nerve block
Study NCT05675657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Block
Description: The patients will receive general anesthesia.
Study NCT05675657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block Type III
Description: Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
Study NCT05675657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
Study NCT06313580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt with added Spices
Description: Consumption of twice daily yogurt with added spices for four weeks.
Study NCT06313580 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Yogurt without added Spices
Description: Consumption of twice daily yogurt without added spices for four weeks.
Study NCT05977231 — intervention group
Intervention type: PROCEDURE
Intervention: BT
Description: A program of BT (including exercise and muscle training)
Study NCT05977231 — intervention group
Intervention type: PROCEDURE
Intervention: bPFMT
Description: A bPFMT program at home
Study NCT05977231 — intervention group
Intervention type: PROCEDURE
Intervention: iVES
Description: An iVES program at home
Study NCT05977231 — intervention group
Intervention type: PROCEDURE
Intervention: BT + bPFMT
Description: Combination of BT and bPFMT
Study NCT05977231 — intervention group
Intervention type: PROCEDURE
Intervention: BT + iVES
Description: Combination of BT and iVES
Study NCT05977231 — intervention group
Intervention type: PROCEDURE
Intervention: bPFMT + iVES
Description: Combination of bPFMT and iVES
Study NCT05264025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: tablet
Study NCT05264025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study NCT05877300 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cellspan™ Esophageal Implant-Adult (CEI)
Description: The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
Study NCT05081453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pavlik harness
Description: The application of a pavlik harness will be carried out in the intervention group. It will follow a protocol similar to that of the treatment of hip dysplasia in terms of follow-up and safety
Study NCT06289075 — intervention group
Intervention type: OTHER
Intervention: Intensive Care Unit (ICU) treatment
Description: ICU treatment
Study NCT06190847 — intervention group
Intervention type: OTHER
Intervention: regular chemoradiotherapy
Description: regular chemoradiotherapy
Study NCT06273644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrates
Description: Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.
Study NCT06273644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrates
Description: Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.
Study NCT06270264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Nociception level index monitoring
Description: Nociception level index (NOL) monitoring (Medasense) is a non- invasive device differentiated from its alternatives by the use of five parameters: heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives.
Study NCT05342389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: a PD-1 antibody
Study NCT05342389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate
Description: an oral tyrosine kinase inhibitor
Study NCT05342389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: an oral tyrosine kinase inhibitor
Study NCT05648942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anemia testing
Description: Patients will undergo a point of care test to identify possible anemia
Study NCT05312151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Open label
Study NCT06270654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: After consent was obtained, patients will be randomised into control group and an intervention group. For patients randomized into the interventional group, bilateral erector spinae plane block will be performed under general anaesthesia in prone position before the operation. An experienced anaesthetist performs this under ultrasound guidance (using curvilinear probe) in a sterile method.~After identifying L3 transverse process, 21G Stimuplex needle will be inserted via in-plane method. Once needle placement is confirmed and aspiration is negative, 20ml of ropivacaine 0.375% with adrenaline 1:200,000 dilution will be given on each side.
Study NCT06270654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin infiltration LA
Description: Pre incision of 0.375% ropivacaine 10ml local infiltration will be given to control group
Study NCT06546371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulator
Description: Electrical stimulation of the dorsal horn to reduce chronic pain.
Study NCT04919928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant and Hearing aid in bimodal solution
Description: Sixty adult participants with bilateral hearing aids (HA) referred for cochlear implantation (CI) will be included in the study. It will be patients who report limited benefit with appropriately fitted HAs in daily speech communication in quiet and in noise. The patients are depending on visual cues for successful communication.~All the referred patients have potential optimal fitted HAs that are no longer sufficient to treat their hearing loss and to improve the daily communication. All the patients will then receive new replacement HAs with the ability to corporate with a CI for one month trial period. One month is considered as a sufficient adaptation period to new replacement HAs according to current clinical practice.~Thirty individuals randomised to receive the intervention with CI to the poorest hearing ear.
Study NCT04919928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral hearing aids
Description: Thirty individuals randomised to the control group will continue use of the new replacement HAs another three months, thus in total of four months of use.
Study NCT05482360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Optimization Interventions
Description: There will be three strategies or bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders and are unknown at this time.
Study NCT06272422 — intervention group
Intervention type: PROCEDURE
Intervention: hip arthroplasty
Description: resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.
Study NCT04823260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Mononucleotide
Description: Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases
Study NCT04823260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour in white capsule resembling NMN
Study NCT05254366 — intervention group
Intervention type: DRUG
Intervention: Remimazolam Tosilate for Injection
Description: Remimazolam Tosilate for Injection
Study NCT04679870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB2064
Description: GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
Study NCT06122714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144 Part A
Description: Part A: Participants will be administered a single oral dose on Day 1.
Study NCT06122714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144 Part B
Description: Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
Study NCT06122714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part A
Description: Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
Study NCT06122714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part B
Description: Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
Study NCT05057195 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Interstitial radiation therapy
Description: From 30 to 50 Gy,
Study NCT05057195 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative external beam therapy
Description: 50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin
Study NCT04915573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen
Description: Sputum will be collected in clean disposable containers
Study NCT05571280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplementation
Description: The Small-quantity lipid-based nutrient supplementation (SQ-LNS) consists of micronutrients delivered in a lipid-based vehicle. All pregnant women (as of 12 weeks self-referred) within households who were randomly included in the study in the nutritional supplementation arm and their children as of 6 months of age will receive the SQ-LNS.~● Pregnant women: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake.~Total = 12/13 months approximately.~● Children from 6 months of age: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake. Total = 18 months.~The distribution will be made by ADECOS on a fortnightly basis.~A family ration will be distributed: family supplementation is presented in a basket of locally produced basic foods that complement the usual diet. The caloric distribution of the basket will be 45% of cereals, 30% of pulses, and 25% in oil, and 1 kg of iodized salt.
Study NCT05571280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Money transfers
Description: The distribution of the amounts will be made through the corresponding financial providers, together with the Municipal or Communal Administration authorities, the Assistants of Community Activities, the Investigator's personnel, and the ADECOS. The distribution frequency will be every 3 months until the end of the study.
Study NCT05571280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard intervention
Description: The activities included are the following:~1. Community interventions against malnutrition and promotion of adequate nutrition: raise awareness of malnutrition and training mothers to recognize signs of malnutrition.~2. Community interventions in promoting hygiene and proper sanitation: a) Promotion of Community-Led Total Sanitation approach (CLTS)strategy: community awareness of the entire population included in the cluster about the dangers of open defecation, and the direct link to malnutrition; b) Promotion of Baby-Wash strategy: to make the community aware of the problems and consequences of unsafe water consumption.~3. Biannual supplementation with vitamin A for children from 6 to 24 months of age.~4. Biannual deworming (albendazole/mebendazole) for children from 12 months to 24 months of age and pregnant women as of 2nd quarter.~5. Malaria prophylaxis with sulfadoxine-pyrimethamine (SP) in pregnant women as of 13 weeks of pregnancy.
Study NCT06618547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENEO 317 Model 2 excimer laser
Description: TENEO 317 Model 2 excimer laser by Transepithelial Photorefractive Keratectomy
Study NCT05465161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sting Mark Fiducial Marker
Description: Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
Study NCT05111561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT05111561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT05111561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05111561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05111561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05111561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06682520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum NEST-Rural Program (Hospital based service model)
Description: NEST-Rural services will include 3-5 nurse encounters and, if indicated, up to 3 social work encounters with mothers and their infants in the postpartum period, postpartum remote blood pressure monitoring, breastfeeding support, infant weight checks, linking mothers and infants to needed social, behavioral, and health-related resources, and integration of service delivery with healthcare providers.
Study NCT06723366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angong Niuhuang Pill (ANP)
Description: Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)
Study NCT06723366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control (Standard treatment)
Description: Blank control
Study NCT05227833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan fumarate (Vonaspire)
Description: Patients assigned to Vonoprazan (vonaspire) tablets will receive a daily dose of 20 mg before breakfast starting from the first day of band ligation.
Study NCT05227833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Patients assigned to Pantoprazole tablets (Controloc OR Antopral OR Perloc) will receive a daily dose of 40 mg before breakfast starting from the first day of band ligation.
Study NCT05227833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Intervention
Study NCT06733766 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound-guided thermal ablation
Description: microwave ablation, radiofrequency ablation, laser ablation
Study NCT06732492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-02 cell infusion
Description: CAR-T cells
Study NCT06732063 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: endodontic retreatment
Description: Re-treatment of previously failed root canal treatments
Study NCT06733896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trigger point pressure
Description: The midpoint of the sternocleidomastoid muscle with abundant nerve distribution and the onset and endpoint of the sternocleidomastoid muscle were used as acupoints, which can relieve localised muscle spasms and promote nerve nutrition.
Study NCT06733896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neck exercises
Description: Manual Cervical Traction Technique and others
Study NCT06732050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nociception guided treatment
Description: For the nociception level-guided group the same standard narcosis will be applied whilst ensuring that the NOL® level value will be maintained between 10 and 25.
Study NCT06733870 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: guided immediate implant surgery
Description: fully guided immediate implant placement and loading
Study NCT06012734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100
Description: IV on day 1 and day 3
Study NCT06012734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV on day 1
Study NCT06282679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: you are asked to return to the hospital for follow-up at weeks 2, 4, 8, and 12
Study NCT05009342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: below-knee soft resin cast
Description: Patients have soft resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
Study NCT05009342 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Below-knee rigid resin cast
Description: Patients have rigid resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
Study NCT04245280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: ropivacaine 0.5% with epinephrine 2.5 mcg/ml
Study NCT04245280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: normal saline solution (NaCl 0.9%)
Study NCT05127122 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo Saline
Study NCT05582564 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: abstract vs concrete texts
Description: The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract descriptive style and language, while the other used a more anecdotical style and concrete language: each group read only one of these articles. Both articles are the same length and describe an episode of vaccine-related thrombosis. The abstract text uses a more formal and impersonal language, reporting more scientific considerations; the concrete text uses a more familiar and emotional style and provides a more anecdotical description of the case. Texts were also weighted according to a concreteness semantic vocabulary. French received translated versions.Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.
Study NCT06489561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system
Description: Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried)
Study NCT04912648 — intervention group
Intervention type: OTHER
Intervention: Longitudinal follow up
Description: Repeat follow up at 3,5 and 10 years
Study NCT05132608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social media-based Health education program
Description: The social media-based health education program consist of 16 minute PNC video in Nepali language guided by Health Belief Model. The video provided general information on postnatal care including frequency, timing, and place providing postnatal care; danger signs of mother and newborn; different services provided at each PNC visit, and the importance of PNC visit. The researcher sent PNC videos through instant messaging (IM) software applications such as Viber, What's App, and Facebook messenger to the intervention group.
Study NCT05549401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F1
Description: QD, PQ
Study NCT05549401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F2
Description: QD, PQ